Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Regeneron Pharmaceuticals (REGN)

Regeneron Pharmaceuticals (REGN)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 79,350,256
  • Shares Outstanding, K 105,720
  • Annual Sales, $ 14,343 M
  • Annual Income, $ 4,505 M
  • EBIT $ 3,578 M
  • EBITDA $ 4,122 M
  • 60-Month Beta 0.40
  • Price/Sales 5.50
  • Price/Cash Flow 17.77
  • Price/Book 2.52

Options Overview Details

View History
  • Implied Volatility 43.50% (+0.94%)
  • Historical Volatility 24.33%
  • IV Percentile 84%
  • IV Rank 75.77%
  • IV High 49.02% on 04/21/25
  • IV Low 26.22% on 11/26/25
  • Expected Move (DTE 4) 24.34 (3.24%)
  • Put/Call Vol Ratio 1.13
  • Today's Volume 537
  • Volume Avg (30-Day) 1,153
  • Put/Call OI Ratio 0.98
  • Today's Open Interest 36,033
  • Open Int (30-Day) 34,268
  • Expected Range 726.07 to 774.75

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 29 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/26
See More
  • Average Estimate $6.21
  • Number of Estimates 7
  • High Estimate $7.82
  • Low Estimate $4.29
  • Prior Year $6.43
  • Growth Rate Est. (year over year) -3.42%

Price Performance

See More
Period Period Low Period High Performance
1-Month
727.96 +3.15%
on 03/24/26
781.21 -3.88%
on 04/01/26
+18.02 (+2.46%)
since 03/20/26
3-Month
727.88 +3.16%
on 03/19/26
815.00 -7.87%
on 02/17/26
+17.10 (+2.33%)
since 01/20/26
52-Week
476.49 +57.59%
on 06/05/25
821.11 -8.55%
on 01/09/26
+187.73 (+33.33%)
since 04/17/25

Most Recent Stories

More News
1 Cash-Heavy Stock with Promising Prospects and 2 We Find Risky

1 Cash-Heavy Stock with Promising Prospects and 2 We Find Risky

FBNC : 59.51 (-0.05%)
REGN : 751.86 (+0.17%)
WBTN : 12.20 (+0.08%)
Earnings Preview: What to Expect From Regeneron Pharmaceuticals' Report

Regeneron Pharmaceuticals is expected to announce its fiscal first-quarter earnings this month, and analysts project a low single-digit earnings drop.

XLV : 147.89 (-0.61%)
$SPX : 7,101.53 (-0.34%)
REGN : 751.86 (+0.17%)
Regeneron and Telix Announce Strategic Radiopharma Collaboration

Regeneron and Telix to co-develop and co-commercialize next-generation radiopharmaceutical therapies in a 50/50 cost and profit-sharing model  Collaboration combines Regeneron’s leading antibody...

TLX : 10.68 (-0.61%)
REGN : 751.86 (+0.17%)
Dupixent® (dupilumab) Approved in the EU as the First Targeted Medicine to Treat Young Children with Chronic Spontaneous Urticaria (CSU)

Approval in CSU for children 2 to 11 years of age is based on data from the LIBERTY-CUPID clinical trial program, including an extrapolation of efficacy data showing that Dupixent significantly reduced...

REGN : 751.86 (+0.17%)
Regeneron (REGN): Buy, Sell, or Hold Post Q4 Earnings?

Regeneron (REGN): Buy, Sell, or Hold Post Q4 Earnings?

REGN : 751.86 (+0.17%)
Regeneron Collaborates with TriNetX to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health Solutions

Regeneron has exclusive opportunity to connect large-scale genomic and proteomic data cohorts to TriNetX’s industry-leading global network of electronic health record data Collaboration will expand...

REGN : 751.86 (+0.17%)
Hims & Hers Health, Regeneron, Biogen, BioMarin Pharmaceutical, and Moderna Shares Are Falling, What You Need To Know

Hims & Hers Health, Regeneron, Biogen, BioMarin Pharmaceutical, and Moderna Shares Are Falling, What You Need To Know

HIMS : 31.22 (+8.33%)
BMRN : 55.19 (+1.01%)
REGN : 751.86 (+0.17%)
MRNA : 54.46 (+1.38%)
BIIB : 183.75 (+3.61%)
EYLEA HD® (aflibercept) Approved by FDA as First and Only Injectable Anti-VEGF with Dosing Intervals Up to 5 Months for Wet Age-related Macular Degeneration (wAMD) and Diabetic Macular Edema (DME)

Approval is based on 96-week data from 2 pivotal trials showing majority of EYLEA HD patients maintained their visual and anatomic improvements with extended dosing intervals New EYLEA HD dosing regimen...

REGN : 751.86 (+0.17%)
Regeneron to Report First Quarter 2026 Financial and Operating Results and Host Conference Call and Webcast on April 29, 2026

TARRYTOWN, N.Y., March 25, 2026 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN ) today announced that it will report its first quarter 2026 financial and operating results on Wednesday,...

REGN : 751.86 (+0.17%)
Dupixent® (dupilumab) Approved in Japan as the First Targeted Medicine to Treat Adults with Bullous Pemphigoid (BP)

Approval in moderate-to-severe patients was based on pivotal trial results showing over four times more Dupixent patients experienced sustained disease remission through Week 36 compared with placebo ...

SAN.FP : 82.030 (+0.01%)
REGN : 751.86 (+0.17%)
SNY : 48.19 (+0.27%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 16% Buy with a Weakest short term outlook on maintaining the current direction.

See More Share

Business Summary

Regeneron is a biotechnology company focused on the discovery, development and commercialization of treatments targeting serious medical conditions. The company's portfolio boasts nine marketed drugs - Eylea, Dupixent, Praluent, Kevzara, Libtayo, Evkeeza, Inmazeb Arcalyst and Zaltrap. The company also...

See More

Key Turning Points

3rd Resistance Point 768.85
2nd Resistance Point 763.73
1st Resistance Point 757.15
Last Price 751.86
1st Support Level 745.45
2nd Support Level 740.33
3rd Support Level 733.75

See More

52-Week High 821.11
Last Price 751.86
Fibonacci 61.8% 689.46
Fibonacci 50% 648.80
Fibonacci 38.2% 608.13
52-Week Low 476.49

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.